Healthcare · Biotechnology
Price
$87.68
Market Cap
$587.4M
Employees
22
Beta
1.54
Avg Volume
168,287
CEO
Chandler D. Robinson
Business Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-47.39
Stock Price: $87.68
EPS (Diluted): -1.85
EPS (Diluted): -1.85
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.51
Stock Price: $87.68
Total Equity: $137.83M
Shares: 7,411,000
Total Equity: $137.83M
Shares: 7,411,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-34.20
Market Cap: $587.37M
Total Debt: $0.00
Cash: $61.83M
EBITDA: -$13.72M
Total Debt: $0.00
Cash: $61.83M
EBITDA: -$13.72M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$422.3M
Market Cap: $587.37M
Total Debt: $0.00
Cash: $61.83M
Total Debt: $0.00
Cash: $61.83M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $87.68
Revenue: $0.00
Shares: 7,411,000
Revenue: $0.00
Shares: 7,411,000
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$16.70M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$13.72M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-12.8%
Net Income: -$13.72M
Total Equity: $137.83M
Total Equity: $137.83M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-13.8%
Operating Income: -$16.70M
Tax Rate: 0.0%
Equity: $137.83M
Total Debt: $0.00
Cash: $61.83M
Tax Rate: 0.0%
Equity: $137.83M
Total Debt: $0.00
Cash: $61.83M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
51.35
Current Assets: $140.46M
Current Liabilities: $2.74M
Current Liabilities: $2.74M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $137.83M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $137.83M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 7,411,000
Shares: 7,411,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$18.60
Total Equity: $137.83M
Shares: 7,411,000
Shares: 7,411,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.65
Operating CF: -$12.20M
CapEx: $0.00
Shares: 7,411,000
CapEx: $0.00
Shares: 7,411,000
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $87.68
Stock Price: $87.68
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$13.72M
Net Income: -$13.72M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares MNPR against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:27pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | $9.1M | $10.5M | $8.8M | $16.2M | $16.7M |
| Operating Income | -$9.1M | -$10.5M | -$8.8M | -$16.2M | -$16.7M |
| Net Income | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M |
| EBITDA | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M |
| EPS | $-0.73 | $-0.83 | $-0.58 | $-1.36 | $-1.85 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:27pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $20.3M | $8.2M | $7.3M | $45.8M | $61.8M |
| Total Current Assets | $20.5M | $13.2M | $7.3M | $60.3M | $140.5M |
| Total Assets | $20.5M | $13.2M | $7.3M | $60.3M | $140.7M |
| Current Liabilities | $1.6M | $3.1M | $1.8M | $5.3M | $2.7M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.6M | $3.1M | $1.8M | $5.3M | $2.9M |
| Total Equity | $18.9M | $10.1M | $5.6M | $55.0M | $137.8M |
| Retained Earnings | -$41.3M | -$51.8M | -$60.2M | -$75.8M | -$89.5M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:27pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M |
| Capital Expenditure | $1 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | -$35.0M |
| Net Change in Cash | $3.6M | -$12.1M | $-920,114 | $38.6M | $16.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 4:23am (4h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$15.4M $3.7M – $28.5M
|
$82.9M $82.9M – $82.9M
|
$162.7M $62.3M – $275.2M
|
$282.1M $107.9M – $477.0M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$36.2M -$54.0M – -$8.5M
|
-$19.9M -$45.0M – $13.4M
|
$8.1M $1.6M – $15.3M
|
$33.0M $6.5M – $62.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:27pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -15.4% | +16.2% | -83.0% | -3.4% |
| Net Income Growth | -15.5% | +20.1% | -85.5% | +12.0% |
| EBITDA Growth | -15.5% | +20.1% | -85.5% | +12.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 4:23am (4h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-31 | Robinson Chandler | M-Exempt | 6,732.00 | $0.00 | $0 |
| 2026-03-31 | Robinson Chandler | M-Exempt | 6,732.00 | $0.00 | $0 |
| 2026-03-31 | Robinson Chandler | F-InKind | 1,972.00 | $54.79 | $108,046 |
| 2026-03-31 | Cittadine Andrew | M-Exempt | 3,514.00 | $0.00 | $0 |
| 2026-03-31 | Cittadine Andrew | F-InKind | 1,571.00 | $54.79 | $86,075 |
| 2026-03-31 | Cittadine Andrew | M-Exempt | 3,514.00 | $0.00 | $0 |
| 2026-03-02 | Rodriguez Susan | A-Award | 48,728.00 | $53.47 | $2.6M |
| 2026-03-02 | Rodriguez Susan | 0.00 | $0.00 | $0 | |
| 2025-01-28 | Robinson Chandler | J-Other | 62,815.00 | $0.00 | $0 |
| 2025-12-31 | Robinson Chandler | M-Exempt | 8,724.00 | $0.00 | $0 |
| 2025-12-31 | Robinson Chandler | M-Exempt | 8,724.00 | $0.00 | $0 |
| 2025-12-31 | Robinson Chandler | F-InKind | 2,558.00 | $65.30 | $167,037 |
| 2025-12-31 | Cittadine Andrew | M-Exempt | 4,326.00 | $0.00 | $0 |
| 2025-12-31 | Cittadine Andrew | F-InKind | 1,889.00 | $65.30 | $123,352 |
| 2025-12-31 | Cittadine Andrew | M-Exempt | 4,326.00 | $0.00 | $0 |
| 2026-01-01 | RIOUX PATRICE | A-Award | 2,000.00 | $65.30 | $130,600 |
| 2025-12-26 | Vu Quan Anh | P-Purchase | 1,500.00 | $69.95 | $104,925 |
| 2025-12-18 | KLAUSNER ARTHUR J | S-Sale | 4,660.00 | $67.06 | $312,500 |
| 2025-12-18 | KLAUSNER ARTHUR J | S-Sale | 461.00 | $68.09 | $31,389 |
| 2025-12-16 | Hendricks Diane | J-Other | 43,499.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for MNPR — it's generated by the pipeline (
market-narrative step).
No community reviews yet for MNPR.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30